- The FDA approved STAAR Surgical Company's (NASDAQ:STAA) EVO/EVO+ Visian Implantable Collamer Lens to correct myopia and myopia with astigmatism. Myopia, also known as nearsightedness or the need for distance vision correction.
- The Company, in a statement, says that the EVO lens is additive, provides quality of vision day & night, does not cause dry eye syndrome, and, if required, can be removed by a doctor.
- EVO offers a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for distance vision correction.
- A U.S. multicenter, prospective clinical investigation confirmed the safety of the EVO family of myopia lenses.
- Read Next: BTIG Upgraded Staar Surgical Stock - Read Why.
- More than 100 clinical papers are available discussing the safety and efficacy of the Visian ICL family of lenses globally.
- Price Action: STAA shares are up 9.47% at $79.86 on the last check Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Why STAAR Surgical's Shares Are Gaining Today
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks